RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Adamas Pharmaceuticals Stock

Adamas Pharmaceuticals ROA 2024

Adamas Pharmaceuticals ROA

0

Ticker

ADMS

ISIN

US00548A1060

WKN

A111X7

In 2024, Adamas Pharmaceuticals's return on assets (ROA) was 0, a 0% increase from the 0 ROA in the previous year.

Adamas Pharmaceuticals Aktienanalyse

What does Adamas Pharmaceuticals do?

Adamas Pharmaceuticals, Inc. is an American biopharmaceutical company specializing in the development of therapies for neurological diseases. It was founded in 2000 by Gregory Went and Mark Gergen and is headquartered in Emeryville, California. The company's goal is to develop groundbreaking therapies that can improve the lives of people with neurological diseases, particularly focusing on the treatment of Parkinson's disease, multiple sclerosis, and epilepsy. Adamas Pharmaceuticals' business model is based on the discovery, development, and commercialization of novel drugs based on patient needs and scientific insights. The company collaborates closely with leading scientists, doctors, and patient organizations to maximize the effectiveness of its medications. Adamas Pharmaceuticals is divided into several business units, each specializing in different neurological diseases, including Parkinson's disease, multiple sclerosis, and epilepsy. The company has developed GOCOVRI, the first and only medication for the treatment of dyskinesias in Parkinson's disease patients. It is also working on medications for multiple sclerosis and epilepsy. Adamas Pharmaceuticals has partnerships with other pharmaceutical companies, including a collaboration with Biogen, a leading biotechnology company specializing in neurological disease therapies. The company is dedicated to making significant advancements in the fight against neurological diseases through its focus on patient needs and collaboration with scientists and doctors. Adamas Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding Adamas Pharmaceuticals's Return on Assets (ROA)

Adamas Pharmaceuticals's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Adamas Pharmaceuticals's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Adamas Pharmaceuticals's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Adamas Pharmaceuticals’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Adamas Pharmaceuticals stock

What is the Return on Assets (ROA) of Adamas Pharmaceuticals this year?

The Return on Assets (ROA) of Adamas Pharmaceuticals is 0 undefined this year.

What was the ROA of Adamas Pharmaceuticals compared to the previous year?

The ROA of Adamas Pharmaceuticals has increased by 0% compared to the previous year.

What consequences do high ROA have for investors of Adamas Pharmaceuticals?

A high ROA is advantageous for investors of Adamas Pharmaceuticals, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in Adamas Pharmaceuticals?

A low ROA can be unfavorable for investors of Adamas Pharmaceuticals as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of Adamas Pharmaceuticals affect the company?

An increase in ROA of Adamas Pharmaceuticals can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of Adamas Pharmaceuticals impact the company?

A reduction in the ROA of Adamas Pharmaceuticals can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of Adamas Pharmaceuticals?

Some factors that can influence the ROA of Adamas Pharmaceuticals include revenue, operating costs, asset structure, and industry average.

Why is the ROA of Adamas Pharmaceuticals important for investors?

The ROA of Adamas Pharmaceuticals is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can Adamas Pharmaceuticals take to improve ROA?

To improve ROA, Adamas Pharmaceuticals can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does Adamas Pharmaceuticals pay?

Over the past 12 months, Adamas Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Adamas Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Adamas Pharmaceuticals?

The current dividend yield of Adamas Pharmaceuticals is .

When does Adamas Pharmaceuticals pay dividends?

Adamas Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Adamas Pharmaceuticals?

Adamas Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Adamas Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Adamas Pharmaceuticals located?

Adamas Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Adamas Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Adamas Pharmaceuticals from 9/29/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/29/2024.

When did Adamas Pharmaceuticals pay the last dividend?

The last dividend was paid out on 9/29/2024.

What was the dividend of Adamas Pharmaceuticals in the year 2023?

In the year 2023, Adamas Pharmaceuticals distributed 0 USD as dividends.

In which currency does Adamas Pharmaceuticals pay out the dividend?

The dividends of Adamas Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Adamas Pharmaceuticals

Our stock analysis for Adamas Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Adamas Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.